Evidence map›Paper›PMID 23607771›Full record

ArticleClinical and experimental immunology2013

Immunization with 60 kD Ro peptide produces different stages of preclinical autoimmunity in a Sjögren's syndrome model among multiple strains of inbred mice.

B T Kurien, A Dsouza, A Igoe, Y J Lee, J S Maier-Moore, T Gordon, M Jackson, R H Scofield

Open access · greenAbstract read
In one paragraph

Article in Clinical and experimental immunology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. A case for IL-6, IL-17A, and nitric oxide in the pathophysiology of Sjögren's syndrome.International journal of immunopathology and pharmacology · 2016
    Article
  11. Article
  12. Mouse Models of Primary Sjogren's Syndrome.Current pharmaceutical design · 2015
    Review
  13. Review
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 3 countries.

B T KurienArthritis & Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, USA.
A Dsouza
A Igoe
Y J Lee
J S Maier-Moore
T Gordon
M Jackson
R H Scofield
Oklahoma Medical Research Foundation · USUniversity of Oklahoma Health Sciences Center · USFlinders University · AU

Funding

Pathogenic B Cells in Sjogren's SyndromeP50AR060804 · NIAMS · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI SIVILS, KATHY L. · 2011 to 2015
$7.9M
Sjogren's model with anti-Ro/La and Salivary Pathology and DysfunctionR01DE017561 · NIDCR · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI SCOFIELD, ROBERT HAL · 2006 to 2010
$1.5M
NIAMS NIH HHS P50 AR060804NIDCR NIH HHS DE017561NIDCR NIH HHS R01 DE017561
6 · The paper itself

Abstract

Sjögren's syndrome is a chronic illness manifested characteristically by immune injury to the salivary and lacrimal glands, resulting in dry mouth/eyes. Anti-Ro [Sjögren's syndrome antigen A (SSA)] and anti-La [Sjögren's syndrome antigen B (SSB)] autoantibodies are found frequently in Sjögren's subjects as well as in individuals who will go on to develop the disease. Immunization of BALB/c mice with Ro60 peptides results in epitope spreading with anti-Ro and anti-La along with lymphocyte infiltration of salivary glands similar to human Sjögren's. In addition, these animals have poor salivary function/low saliva volume. In this study, we examined whether Ro-peptide immunization produces a Sjögren's-like illness in other strains of mice. BALB/c, DBA-2, PL/J, SJL/J and C57BL/6 mice were immunized with Ro60 peptide-274. Sera from these mice were studied by immunoblot and enzyme-linked immunosorbent assay for autoantibodies. Timed salivary flow was determined after pharmacological stimulation, and salivary glands were examined pathologically. We found that SJL/J mice had no immune response to the peptide from Ro60, while C57BL/6 mice produced antibodies that bound the peptide but had no epitope spreading. PL/J mice had epitope spreading to other structures of Ro60 as well as to La, but like C57BL/6 and SJL/J had no salivary gland lymphocytic infiltration and no decrement of salivary function. DBA-2 and BALB/c mice had infiltration but only BALB/c had decreased salivary function. The immunological processes leading to a Sjögren's-like illness after Ro-peptide immunization were interrupted in a stepwise fashion in these differing mice strains. These data suggest that this is a model of preclinical disease with genetic control for epitope spreading, lymphocytic infiltration and glandular dysfunction.

Indexed as

Disease Models, AnimalAmino Acid SequenceAnimalsAntibodies, AntinuclearAutoantigensAutoimmunityCarbacholEpitopesFreund's AdjuvantH-2 AntigensHaplotypesImmunizationLymphocyte SubsetsMaleMiceMice, Inbred StrainsAntibodies, AntinuclearAutoantigensCarbacholEpitopesFreund's AdjuvantH-2 AntigensPeptide FragmentsReceptor, Muscarinic M3RibonucleoproteinsRNA, Small CytoplasmicSsa2 protein, mouseSS-A antibodiesSS-B Antigen

Identifiers

PMID23607771
PMCPMC3694536
OpenAlexW1576383998

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.